Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2012 (2012), Article ID 107180, 16 pages
http://dx.doi.org/10.1155/2012/107180
Clinical Study

A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

1Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
2University Medical Center Hamburg-Eppendorf, Hamburg, Germany
3Instituto de Nefrología, Buenos Aires, Argentina
4Fundación Favaloro, Buenos Aires, Argentina
5The Queen Elizabeth Hospital, Adelaide, SA, Australia
6Renal Transplant Unit, Hospital Clinic University of Barcelona, Barcelona, Spain
7Indiana University School of Medicine, Indianapolis, IN, USA
8University of British Columbia and Syreon Corporation, Vancouver, BC, Canada

Received 28 December 2011; Accepted 3 May 2012

Academic Editor: Andreas Zuckermann

Copyright © 2012 Bertram L. Kasiske et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. K. Law, “Rapamycin: an anti-cancer immunosuppressant?” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 47–60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Augustine, K. A. Bodziak, and D. E. Hricik, “Use of sirolimus in solid organ transplantation,” Drugs, vol. 67, no. 3, pp. 369–391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Neuhaus, J. Klupp, and J. M. Langrehr, “mTOR inhibitors: an overview,” Liver Transplantation, vol. 7, no. 6, pp. 473–484, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. B. D. Kahan, “Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study,” Lancet, vol. 356, no. 9225, pp. 194–202, 2000. View at Google Scholar · View at Scopus
  5. A. S. MacDonald, “A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts,” Transplantation, vol. 71, no. 2, pp. 271–280, 2001. View at Google Scholar · View at Scopus
  6. G. Ciancio, G. W. Burke, J. J. Gaynor et al., “A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation—I. Drug interactions and rejection at one year,” Transplantation, vol. 77, no. 2, pp. 244–251, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Gonwa, R. Mendez, H. C. Yang, S. Weinstein, S. Jensik, and S. Steinberg, “Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months,” Transplantation, vol. 75, no. 8, pp. 1213–1220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Mendez, T. Gonwa, H. C. Yang, S. Weinstein, S. Jensik, and S. Steinberg, “A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year,” Transplantation, vol. 80, no. 3, pp. 303–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Ciancio, G. W. Burke, J. J. Gaynor et al., “A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year,” Transplantation, vol. 77, no. 2, pp. 252–258, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. D. Kahan and W. G. Kramer, “Median effect analysis of efficacy versus adverse effects of immunosuppressants,” Clinical Pharmacology and Therapeutics, vol. 70, no. 1, pp. 74–81, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. B. D. Kahan, “Sirolimus: a comprehensive review,” Expert Opinion on Pharmacotherapy, vol. 2, no. 11, pp. 1903–1917, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Knight and B. D. Kahan, “The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?” Kidney International, vol. 70, no. 6, pp. 994–999, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. V. Mulay, N. Hussain, D. Fergusson, and G. A. Knoll, “Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials,” American Journal of Transplantation, vol. 5, no. 7, pp. 1748–1756, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. C. Webster, V. W. S. Lee, J. R. Chapman, and J. C. Craig, “Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials,” Transplantation, vol. 81, no. 9, pp. 1234–1248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Flechner, D. Goldfarb, C. Modlin et al., “Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine,” Transplantation, vol. 74, no. 8, pp. 1070–1076, 2002. View at Google Scholar · View at Scopus
  16. C. G. Groth, L. Bäckman, J. M. Morales et al., “Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine,” Transplantation, vol. 67, no. 7, pp. 1036–1042, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kreis, J. M. Cisterne, W. Land et al., “Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients,” Transplantation, vol. 69, no. 7, pp. 1252–1260, 2000. View at Google Scholar · View at Scopus
  18. M. D. Stegall, T. S. Larson, M. Prieto et al., “Kidney transplantation without calcineurin inhibitors using sirolimus,” Transplantation Proceedings, vol. 35, no. 3, supplement, pp. 125S–127S, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. P. G. P. Machado, C. Garcia, C. R. Felipe et al., “A single-center open label randomized trial of the safety and efficacy of the use of sirolimus versus azathioprine in one-haplotype living related kidney transplant recipients—preliminary results,” Transplantation Proceedings, vol. 33, no. 1-2, pp. 1074–1075, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Ekberg, H. Tedesco-Silva, A. Demirbas et al., “Reduced exposure to calcineurin inhibitors in renal transplantation,” New England Journal of Medicine, vol. 357, no. 25, pp. 2562–2575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Demopoulos, M. Polinsky, G. Steele et al., “Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials,” Transplantation Proceedings, vol. 40, no. 5, pp. 1407–1410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. A. Benavides, V. B. Pollard, S. Mauiyyedi, H. Podder, R. Knight, and B. D. Kahan, “BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes,” Transplantation, vol. 84, no. 1, pp. 83–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. P. Monaco, “The role of mTOR inhibitors in the management of posttransplant malignancy,” Transplantation, vol. 87, no. 2, pp. 157–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. F. P. Schena, M. D. Pascoe, J. Alberu et al., “Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial,” Transplantation, vol. 87, no. 2, pp. 233–242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. R. Earnshaw, C. N. Graham, W. D. Irish, R. Sato, and M. A. Schnitzler, “Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1807–1816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. Mulay, S. Cockfield, R. Stryker, D. Fergusson, and G. A. Knoll, “Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence,” Transplantation, vol. 82, no. 9, pp. 1153–1162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Kaplan, J. Schold, T. Srinivas et al., “Effect of sirolimus withdrawal in patients with deteriorating renal function,” American Journal of Transplantation, vol. 4, no. 10, pp. 1709–1712, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Mota, M. Arias, E. I. Taskinen et al., “Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years,” American Journal of Transplantation, vol. 4, no. 6, pp. 953–961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Oberbauer, H. Kreis, R. W. G. Johnson et al., “Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study,” Transplantation, vol. 76, no. 2, pp. 364–370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Oberbauer, G. Segoloni, J. M. Campistol et al., “Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation,” Transplant International, vol. 18, no. 1, pp. 22–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Pearson, R. Wali, H. Shidban, A. Patel, L. Chan, and D. Ptel, “Spare-The-Nephron (STN) Trial: one-year interim efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplants,” American Journal of Transplantation, vol. 6, supplement 2, p. 432, 2006. View at Google Scholar
  32. G. Stallone, S. Di Paolo, A. Schena et al., “Early withdrawal of cyclosporine a improves 1-year kidney graft structure and function in sirolimus-treated patients,” Transplantation, vol. 75, no. 7, pp. 998–1003, 2003. View at Google Scholar · View at Scopus
  33. H. Ekberg, “Calcineurin inhibitor sparing in renal transplantation,” Transplantation, vol. 86, no. 6, pp. 761–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. K. Wali and M. R. Weir, “Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?” Current Opinion in Organ Transplantation, vol. 13, no. 6, pp. 614–621, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Kalata, P. Martus, H. Zettl et al., “Differences between clinical trial participants and patients in a population-based registry: the german rectal cancer study vs. the rostock cancer registry,” Diseases of the Colon and Rectum, vol. 52, no. 3, pp. 425–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. R. W. Sanson-Fisher, B. Bonevski, L. W. Green, and C. D'Este, “Limitations of the randomized controlled trial in evaluating population-based health interventions,” American Journal of Preventive Medicine, vol. 33, no. 2, pp. 155–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. R. W. Yeh and A. S. Go, “Rethinking the epidemiology of acute myocardial infarction: challenges and opportunities,” Archives of Internal Medicine, vol. 170, no. 9, pp. 759–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. B. Ma, E. P. Hui, and T. S. Mok, “Population-based differences in treatment outcome following anticancer drug therapies,” The Lancet Oncology, vol. 11, no. 1, pp. 75–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. D. Pescovitz, N. Nezakatgoo, M. I. Lorber et al., “Prospective observational study of sirolimus as primary immunosuppression after renal transplantation,” Transplantation, vol. 88, no. 8, pp. 1010–1018, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. H. Briggs and A. R. Levy, “Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?” PharmacoEconomics, vol. 24, no. 11, pp. 1079–1086, 2006. View at Google Scholar · View at Scopus
  41. V. L. Re and B. L. Strom, “The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 7, pp. 818–825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Etminan and A. Samii, “Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs,” Pharmacotherapy, vol. 24, no. 8, pp. 964–969, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies,” Journal of Clinical Epidemiology, vol. 61, no. 4, pp. 344–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T. R. Srinivas and H. U. Meier-Kriesche, “Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. S101–S116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Hennessy, “Use of health care databases in pharmacoepidemiology,” Basic and Clinical Pharmacology and Toxicology, vol. 98, no. 3, pp. 311–313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Benson and A. J. Hartz, “A comparison of observational studies and randomized, controlled trials,” New England Journal of Medicine, vol. 342, no. 25, pp. 1878–1886, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Concato, N. Shah, and R. I. Horwitz, “Randomized, controlled trials, observational studies, and the hierarchy of research designs,” New England Journal of Medicine, vol. 342, no. 25, pp. 1887–1892, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. K. M. MacDonald, S. Vancayzeele, A. Deblander, and I. L. Abraham, “Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: application to mild and moderate dementia,” Nursing Clinics of North America, vol. 41, no. 1, pp. 105–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. D. B. Kaufman, R. Shapiro, M. R. Lucey, W. S. Cherikh, R. T. Bustami, and D. B. Dyke, “Immunosuppression: practice and trends,” American Journal of Transplantation, vol. 4, no. 9, supplement, pp. 38–53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. K. A. Barraclough, D. N. Landsberg, R. J. Shapiro et al., “A matched cohort pharmacoepidemiological analysis of steroid free immunosuppression in renal transplantation,” Transplantation, vol. 87, no. 5, pp. 672–680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Dmitrienko, R. Balshaw, G. MacHnicki, R. J. Shapiro, and P. A. Keown, “Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines,” Transplantation, vol. 87, no. 4, pp. 570–577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. L. Heilman, C. Cortese, X. J. Geiger et al., “Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal,” Transplantation, vol. 93, no. 1, pp. 47–53, 2012. View at Publisher · View at Google Scholar
  53. M. Naesens, “Switching from calcineurin inhibitors to mammalian target of rapamycin inhibitors—finally caught the right wave?” Transplantation, vol. 92, no. 7, pp. 728–730, 2011. View at Publisher · View at Google Scholar
  54. D. W. Hanto and R. Chudzinski, “What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?” Transplantation, vol. 87, no. 2, pp. 164–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Liew, G. S. C. Chiang, and A. Vathsala, “Factors associated with proteinuria in renal transplant recipients treated with sirolimus,” Transplant International, vol. 22, no. 3, pp. 313–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Abramowicz, K. Hadaya, M. Hazzan et al., “Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects,” Nephrology Dialysis Transplantation, vol. 23, no. 11, pp. 3727–3729, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Letavernier and C. Legendre, “mToR inhibitors-induced proteinuria: mechanisms, significance, and management,” Transplantation Reviews, vol. 22, no. 2, pp. 125–130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Letavernier, P. Bruneval, S. Vandermeersch et al., “Sirolimus interacts with pathways essential for podocyte integrity,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 630–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Vollenbröker, B. George, M. Wolfgart, M. A. Saleem, H. Pavenstädt, and T. Weide, “mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes,” American Journal of Physiology, vol. 296, no. 2, pp. F418–F426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill, “Sirolimus is associated with new-onset diabetes in Kidney transplant recipients,” Journal of the American Society of Nephrology, vol. 19, no. 7, pp. 1411–1418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. O. Heisel, R. Heisel, R. Balshaw, and P. Keown, “New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis,” American Journal of Transplantation, vol. 4, no. 4, pp. 583–595, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. V. W. S. Lee and J. R. Chapman, “Sirolimus: its role in nephrology,” Nephrology, vol. 10, no. 6, pp. 606–614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. F. K. Port, “Role of observational studies versus clinical trials in ESRD research,” Kidney International, vol. 57, no. 74, pp. S3–S6, 2000. View at Google Scholar · View at Scopus
  64. T. Greene, “Are observational studies “just as effective” as randomized clinical trials?” Blood Purification, vol. 18, no. 4, pp. 317–322, 2000. View at Google Scholar · View at Scopus
  65. H. Kreis, R. Oberbauer, J. M. Campistol et al., “Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 809–817, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Citterio, V. Sparacino, P. Altieri et al., “Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid,” Transplantation Proceedings, vol. 37, no. 2, pp. 827–829, 2005. View at Publisher · View at Google Scholar · View at Scopus